Literature DB >> 8638997

Prevalence of undiagnosed pernicious anemia in the elderly.

R Carmel1.   

Abstract

BACKGROUND: Existing information about the prevalence of pernicious anemia is largely based on older surveys that favored florid manifestations, tended to be retrospective analyses of previously diagnosed disease, and usually studied homogeneous European populations. The lack of current data in the United States has, among other things, hampered discussions of the proposal to increase folate intake by the general population.
OBJECTIVE: To estimate the prevalence of undiagnosed and untreated pernicious anemia among the elderly.
METHODS: A prospective survey of cobalamin levels and anti-intrinsic factor antibody was done in the elderly. Blood testing was done in 729 people aged 60 years or older and follow-up assessment with the Schilling test and other tests was offered when results were abnormal.
RESULTS: Seventeen subjects were found to have pernicious anemia, usually with only minimal clinical manifestations of cobalamin deficiency. Although cobalamin deficiency had been suspected by the physicians of three subjects, they had been treated inadequately and still had evidence of deficiency. Excluding these three partially treated subjects from the analysis, 1.9% of the survey population had unrecognized and untreated pernicious anemia. The prevalence was 2.7% in women and 1.4% in men; 4.3% of the black women and 4.0% of the white women had pernicious anemia.
CONCLUSIONS: Undiagnosed pernicious anemia is a common finding in the elderly, especially among black and white women. If these findings can be extrapolated, almost 800000 elderly people in the United States have undiagnosed and untreated pernicious anemia, and, thus, would be at possible risk for masked cobalamin deficiency if exposed to large amounts of folate. This number does not include those elderly with cobalamin deficiency caused by other disorders or the still unknown number of younger people with unrecognized pernicious anemia and other causes of deficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638997

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  45 in total

1.  Autoantibodies as predictors of disease.

Authors:  D Leslie; P Lipsky; A L Notkins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review.

Authors:  Lindsay H Allen; Joshua W Miller; Lisette de Groot; Irwin H Rosenberg; A David Smith; Helga Refsum; Daniel J Raiten
Journal:  J Nutr       Date:  2018-12-01       Impact factor: 4.798

3.  Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes.

Authors:  Wiebke Schrempf; Marco Eulitz; Volker Neumeister; Gabriele Siegert; Rainer Koch; Heinz Reichmann; Alexander Storch
Journal:  J Neurol       Date:  2010-10-02       Impact factor: 4.849

4.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 5.  Host factors are important in determining clinical outcomes of Helicobacter pylori infection.

Authors:  Tsutomu Chiba; Hiroshi Seno; Hiroyuki Marusawa; Yoshio Wakatsuki; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

6.  How I treat cobalamin (vitamin B12) deficiency.

Authors:  Ralph Carmel
Journal:  Blood       Date:  2008-07-07       Impact factor: 22.113

7.  Human vitamin B12 absorption measurement by accelerator mass spectrometry using specifically labeled (14)C-cobalamin.

Authors:  Colleen Carkeet; Stephen R Dueker; Jozsef Lango; Bruce A Buchholz; Joshua W Miller; Ralph Green; Bruce D Hammock; John R Roth; Peter J Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 8.  Is it time for vitamin B-12 fortification? What are the questions?

Authors:  Ralph Green
Journal:  Am J Clin Nutr       Date:  2009-01-13       Impact factor: 7.045

9.  Inhibitory effects of Helicobacter pylori infection on murine autoimmune gastritis.

Authors:  M Ohana; K Okazaki; C Oshima; K Kawasaki; T Fukui; H Tamaki; M Matsuura; M Asada; T Nishi; K Uchida; S Uose; H Nakase; M Iwano; Y Matsushima; H Hiai; T Chiba
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 10.  Autoimmune gastritis: Pathologist's viewpoint.

Authors:  Irene Coati; Matteo Fassan; Fabio Farinati; David Y Graham; Robert M Genta; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.